ctDNA analysis in plasma samples from patients with advanced breast cancer has shown that acquired mutations of ESR1 are a major driver of resistance to fulvestrant/palbociclib combination therapy [34,35,36]. This evidence concerns the gene ESR1 and breast carcinoma.